BCRX Quote, Financials, Valuation and Earnings

Hologic, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of 17.85%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Hologic, Inc.'s return on equity of 11.59%.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.60, signalling upside risk potential of 173.57%. On the other hand Hologic, Inc. has an analysts' consensus of $76.50 which suggests that it could grow by 2.69%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Hologic, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Hologic, Inc..

BioCryst Pharmaceuticals, Inc. has a beta of 0.909, which suggesting that the stock is 9.061% less volatile than S&P 500. In comparison Hologic, Inc. has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.745%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Hologic, Inc. pays out -- of its earnings as a dividend.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are smaller than Hologic, Inc. quarterly revenues of $1B. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is lower than Hologic, Inc.'s net income of $187.3M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Hologic, Inc.'s PE ratio is 30.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.77x versus 4.13x for Hologic, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of 21.47%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Johnson & Johnson's return on equity of 33.27%.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.60, signalling upside risk potential of 173.57%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.73%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Johnson & Johnson, analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Johnson & Johnson.

BioCryst Pharmaceuticals, Inc. has a beta of 0.909, which suggesting that the stock is 9.061% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.47% to investors and pays a quarterly dividend of $1.30 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are smaller than Johnson & Johnson quarterly revenues of $24B. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is lower than Johnson & Johnson's net income of $5.2B. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 20.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.77x versus 5.47x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

KalVista Pharmaceuticals, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of -361.39%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.60, signalling upside risk potential of 173.57%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 96.33%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than KalVista Pharmaceuticals, Inc..

BioCryst Pharmaceuticals, Inc. has a beta of 0.909, which suggesting that the stock is 9.061% less volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.135, suggesting its less volatile than the S&P 500 by 113.476%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are larger than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.77x versus 54.78x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viatris, Inc. has a net margin of 8.09% compared to BioCryst Pharmaceuticals, Inc.'s net margin of -3.41%. BioCryst Pharmaceuticals, Inc.'s return on equity of -- beat Viatris, Inc.'s return on equity of -21.75%.

BioCryst Pharmaceuticals, Inc. has a consensus price target of $20.60, signalling upside risk potential of 173.57%. On the other hand Viatris, Inc. has an analysts' consensus of $12.1250 which suggests that it could fall by -0.94%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Viatris, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Viatris, Inc..

BioCryst Pharmaceuticals, Inc. has a beta of 0.909, which suggesting that the stock is 9.061% less volatile than S&P 500. In comparison Viatris, Inc. has a beta of 0.843, suggesting its less volatile than the S&P 500 by 15.721%.

BioCryst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris, Inc. offers a yield of 3.92% to investors and pays a quarterly dividend of $0.12 per share. BioCryst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viatris, Inc. pays out 90.63% of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioCryst Pharmaceuticals, Inc. quarterly revenues are $159.4M, which are smaller than Viatris, Inc. quarterly revenues of $3.8B. BioCryst Pharmaceuticals, Inc.'s net income of $12.9M is higher than Viatris, Inc.'s net income of -$128.2M. Notably, BioCryst Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Viatris, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioCryst Pharmaceuticals, Inc. is 2.77x versus 1.03x for Viatris, Inc.. Usually stocks with elevated PS ratios are considered overvalued.